comparemela.com

Latest Breaking News On - Simple endoscopy score - Page 1 : comparemela.com

AbbVie s SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn s Disease

SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment of adult.

Exchange commissionAbbvie ltdDrug administrationEuropean medicines agencyAbbvie incCrohn colitis foundation of americaDisease activity indexSimple endoscopy scoreImportant safety informationMedication guideConsumer brief summaryPregnancy registryFull prescribing informationAllergan aestheticsPrivate securities litigation reform actQuarterly reports

Risankizumab Bests Ustekinumab in Head-to-Head SEQUENCE Trial

Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.

Laurent peyrin birouletRoopal thakkarDrug administrationDevelopment in regulatory affairsUniversity hospital of nancyImage analysis group laurent peyrin birouletNews centerInfinity instituteImage analysis groupUniversity hospitalSimple endoscopy scoreRegulatory affairsMet all primarySecondary endpoints versus stelaraHead to studyOnly specific

Risankizumab vs Ustekinumab in Patients With Crohn Disease: Trial Results

Head-to-head study compared risankizumab (Skyrizi) to ustekinumab (Stelara) in patients with moderately to severely active Crohn disease.

Crohn disease activity indexSimple endoscopy scoreCrohn disease

Operational Highlights and Financial Results for the Period

Mesoblast Prepares for Resubmission of Biologics License Application.

United statesBaylor college of medicineAmyl lightnerSilviu itescuEric roseEmerson perinTexas heart instituteNational institutes of healthBiomedical advanced researchDrug administrationDevelopment authorityResearch developmentInternational consortiumAustralian securities exchangeOffice of tissuesDepartment of colon

Rapid Improvement and Remission in Patients With Refractory

Results of First Patient Cohort from Randomized Controlled Study Presented at Congress of European Crohn’s and Colitis Organisation (ECCO).

United statesAmyl lightnerEric roseGastrointest endoscPaul hughesGlobaldata pharmapointNadine woloshinColitis foundationAustralian securities exchangeDepartment of colonMesoblast limited nasdaqCorporate communications investorsColitis organisationEuropean crohnAssociate professorRectal surgery

vimarsana © 2020. All Rights Reserved.